

|                       |  |
|-----------------------|--|
| <b>Date and Time:</b> | <b>21<sup>st</sup> October 2011; 10.00 – 16.00 hrs</b> |
|-----------------------|--|

|   |  |
|---|--|
| <b>Minutes:</b>   |  |
| <b>2nd Guideline Development Group Meeting</b>            |  |
| <b>Place:</b>   | Boardroom, Level 5, 180 Great Portland Street, London, W1W 5QZ   |
| <b>Present:</b>   | <p>Nik Hirani (Chair)<br/>           Angela Key<br/>           Geraldine Burge<br/>           Malcolm Weallans<br/>           Melissa Hippard<br/>           Nicholas Harrison<br/>           Nick Streaton<br/>           Patrick Wilson<br/>           Richard Hubbard<br/>           Tessa Lewis</p> <p>Vicki Pollitt, Health Economist<br/>           Izaba Younis, Research Fellow<br/>           Zahra Naqvi, Research Fellow<br/>           Nina Balachander, Senior Research Fellow and Project Manager<br/>           Vanessa Delgado Nunes, Guideline Lead<br/>           Sue Latchem, Operations Director<br/>           Daria Bilan, Information Scientist (pm only)<br/>           Maggie Westby, Clinical Effectiveness Lead<br/>           Kate Kelley Associate Director</p> |
| <b>In attendance:</b>                                     |  |
| Clifford Middleton, NICE Guidelines Commissioning Manager |  |
| <b>Apologies:</b>   |  |
| Sue Copley<br>Annette Duck<br>Anne Millar                 |  |

**Notes**

1. Nik Hirani welcomed the group to the second GDG meeting. Apologies were received from Sue Copley, Annette Duck and Anne Millar. The Chair asked all GDG members to declare any relevant conflicts of interest.  
  
 GB declared that her husband is the principle investigator of all the IPF studies she has been involved with since 2003, which includes involvement with Pirfenedone, Vargate and Gamma interferone. GB attended two IPF meetings sponsored by Boeringher Ingleheim and one by Intermune at the ERS in September. GB also attended a Patient Group Advisory Panel in Manchester. organised by WG Consulting. GB is also due to give a lecture to regional physiotherapist on IPF in the upcoming month.

## Notes

RH declared that his department had been given a grant from MRC to study the natural history and aetiology of IPF. He is also part of a consortium on biomarkers for IPF for GSK.

No actions were taken following these declarations and none of the GDG members withdrew as no recommendations were discussed.

2. Each of the following presentations were given:
  - Guidelines, decision making and GRADE - Maggie Westby
  - Clinical outcomes and minimal important difference (MIDs) in IPF- Nik Hirani and Vanessa Nunes
  - Evidence review on pharmacological treatments in people with IPF - Zahra Naqvi, Izaba Younis & Vicky Pollit
  - Making sense of the evidence summary table - Kate Kelley
  - HE plan – Vicky Pollit
3. Nik Hirani presented definitions on the IPF guideline outcomes as listed in the scope. The GDG were asked to provide feedback on which outcomes were relevant to each review question.
4. Zahra Naqvi and Izaba Younis presented the evidence review for pharmacological interventions in people with IPF and Vicky Pollit presented the HE considerations. Evidence for the drug treatments as listed in the scope were presented and how to evaluate the evidence using the summary of evidence tables was presented by Kate Kelley.
5. The GDG were asked to prioritise the clinical questions for economic analysis.
6. The GDG were asked to provide feedback on the review questions which were discussed at GDG meeting 1. They focussed on, when to initiate pharmacological treatment, for how long and in which combination, and pulmonary rehabilitation. As the session overrun, it was decided that presentations on Decision making and linking evidence to recommendations would be revisited at GDG meeting 3.
7. Any other business: Nina Balachander highlighted that a NICE Technology Appraisal (TA) on Pirfenidone is in development and that Nik Hirani and Vanessa Nunes will act as liaison points should any GDG members want to consult on the TA.

The meeting closed at 16.00 hrs.

### **Date, time and venue of the next meeting**

2<sup>nd</sup> December 2011, 10:00 – 16:00hrs, RCP Pickering Room